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 The glucagon-like peptide-1 receptor (GLP-1R) is implicated in the pancreatic signaling 
pathway necessary for insulin secretion.  As such, selective stimulation of GLP-1R may mitigate 
the hyperglycemic effects of type 2 diabetes mellitus (T2DM).  Previous studies demonstrate that 
the non-peptide small molecule T-0632 (T-06) binds GLP-1R without generating a downstream 
response.  We intend to improve the current understanding of GLP-1R binding and signal 
propagation by chemically modifying T-06 to increase the extent of GLP-1R active site 
interaction.  To do this, we produced an analog of T-06 in which an amine group was inserted at 
the standard carboxylic acid locus. In addition to altering enzyme-substrate interactions in its 
own right, this amine group also served as an attachment site for a His-Gly-Glu tripeptide, which 
was assembled via solution-phase peptide synthesis. This tripeptide is believed to be of particular 
physiological import in terms of binding and activating GLP-1R in vivo. We expect this T-06 
analog to interact with the GLP-1R binding site in a way that mimics binding and activation 
events between GLP-1R and its natural substrate, thereby reproducing the conditions necessary 
for GLP-1R activation. Future studies will determine whether these small molecule ligand 













Type 2 Diabetes 
 Type 2 diabetes mellitus (T2DM) is a global health concern, affecting an estimated 371 
million people worldwide.
1
 According to the Center for Disease Control, diabetes-associated 
complications were the seventh leading cause of death in 2010.
2
 Although the mechanisms of 
T2DM onset and progression span several organ systems, the primary symptom associated with 
T2DM is hyperglycemia, or elevated levels of blood-borne glucose.
3
 If left untreated, however, 
the long-term effects of T2DM include blindness, heart disease, and kidney failure.
4
 Although 
healthy diet and exercise are somewhat effective in managing hyperglycemia, additional 
pharmacological treatments are necessary in order for diabetic patients to fully manage their 
symptoms.
5
 As such, T2DM is a topic of intense investigation in academic, medical, and 
pharmaceutical institutions. 
 In a healthy individual, food is converted to glucose through digestive processes and 
released into the bloodstream through cellular channels in the small intestine. This triggers the 
release of the digestive hormones gastric inhibitory polypeptide (GIP) and glucagon-like peptide-
1 (GLP-1) from intestinal K- and L-cells, respectively.
2
 GIP and GLP-1 localize to the 
membranes of pancreatic β-cells, where they bind and activate associated transmembrane 
receptors.
6
 Activation of these receptors generates a molecular signaling cascade that results in 
the production and secretion of insulin into the bloodstream.
1, 3-4
 Once introduced to the 
bloodstream, insulin promotes glucose uptake into tissue cells throughout the body for storage or 






Figure 1. Schematic of Type 2 Diabetes: Physiological Effects. The mechanisms of type 2 
diabetes mellitus are shown. (1) Digestion produced glucose from ingested food. (2) Glucose 
passes through the small intestine into the bloodstream. (3) In response, the pancreas releases 
hormones to stimulate insulin production. (4) The quantity of insulin produced is insufficient for 
glucose absorption by somatic tissues as a result of insulin insensitivity. (5) Glucose remains in 




 This process, known as the incretin effect, is impaired in diabetic individuals.
5
 A number 
of factors, possibly acting in concert, could result in a compromised incretin system. For 
instance, the mechanisms of insulin production or secretion could be damaged or defective, 
resulting in reduced concentrations of blood-borne insulin.
6
 Additionally, tissue cells may not be 
responsive to the concentration of insulin produced, a phenomenon known as insulin 
insensitivity.
3, 6
 Regardless of the cause, the body attempts to compensate for its defective 
incretin effect by upregulating the activity of the pancreatic β-cells. This in turn promotes β-cell 
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burnout and apoptosis. With fewer available β-cells, the hyperglycemic effects are augmented, 
expediting the progression of T2DM and its associated effects.
1, 4
  
 Current pharmacological research has approached T2DM treatment with respect to 
insulin production. In an effort to circumvent insulin insensitivity, many proposed treatment 
methods involve generating sufficiently high insulin concentrations to facilitate glucose uptake 
in the body's tissues.
3, 5
 Insulin injection, a standard diabetes treatment, is one such way to 
accomplish this.
5
 However, insulin has been observed to cause weight gain and high blood 
pressure in patients, both of which amplify the risk of heart disease in an already susceptible 
population.
7-8
 Moreover, a treatment regimen of 2-3 insulin injections per day reduces patient 
compliance.
8
 Alternative means of insulin upregulation have been explored; a broad branch of 
modern pharmacological study has focused on the administration of recombinant proteins, 
namely incretin hormones, in order to combat hyperglycemia.
6
  
GLP-1 and Analogs 
 As an essential incretin hormone, GLP-1 and its associated receptor, GLP-1R, have been 
extensively studied for their potential in T2DM therapeutics. GLP-1 is a 30-residue polypeptide 
encoded by the proglucagon gene.
9
 Following translation, the first 6 residues of the N-terminus 
are cleaved to yield GLP-1 in its mature form, (commonly referred to as GLP-17-36).
9
 Its structure 
consists of an N-terminal loop containing primarily polar residues and an amphipathic α-helix 
(Figure 2A,B).
10-11
 Manufactured in the intestinal L-cells, GLP-1 is secreted into the bloodstream 
in response to carbohydrate and lipid ingestion.
9
 Due to its role in the incretin effect, GLP-1 is 
characterized as an insulin inducer.
9-10
 Studies by Toft-Nelsen and Kjems revealed that the 
injection of GLP-1 hormone immediately following a meal significantly decreased blood glucose 
levels and increased satiety among diabetic patients.
7, 12
 However, these effects are short-lived; 
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native GLP-1 has a half-life of approximately 1 minute, as it is rapidly hydrolyzed by dipeptidyl 
peptidase 4 (DPP-IV).
6, 8, 12-13
 DPP-IV cleaves GLP-1 between its second and third residues, 
rendering GLP-1 ineffective in binding and activating GLP-1R.
8
 Due to its short half-life, very 
little GLP-1 arrives at the pancreatic β-cell intact. 
 DPP-IV degradation makes GLP-1 an inefficient treatment method in its own right. 
However, small modifications to the molecular structure of GLP-1 have generated an entire field 
of pharmacological therapies to treat T2DM.
6, 14
 For instance, the marketed pharmaceutical 
exenatide (brand names, Byetta and Bydurean), is a synthetic version of exendin-4 (Ex-4), a 
polypeptide extracted from gila monster saliva.
14-15
 Sequence alignment revealed that Ex-4 
shares 53% sequence homology with GLP-1 (Figure 2A, C).
13, 15
 An important distinction 
between Ex-4 and its homolog is the alanine-to-glycine substitution at the second residue, thus 
preventing DPP-IV recognition and digestion (Figure 2A).
11
 Exenatide has a similar 
pharmacological identity to GLP-1.
15
 As a matter of fact, evidence suggests that exendin-4 may 
bind the GLP-1 receptor with higher affinity that GLP-1 itself.
16
 According to clinical trials by 
Iltz and colleagues, exenatide reduced fasting plasma glucose concentrations in diabetic 
patients.
17
 Dose-dependent weight loss was also observed in these patients. Although exendin-4 
and other GLP-1 mimetics are effective long-term treatment options for T2DM, there is 
substantial room for improvement. In particular, the relatively short half-life of GLP-1 mimetics 
requires that individuals with diabetes receive multiple injections throughout the day.
14
 Like 
insulin, GLP-1 mimetic injections are associated with limited patient compliance. Therefore, 
small-molecule pharmaceuticals pose a potential solution as an orally-administered drug. Such 




Figure 2. Structural 
Comparison of GLP-1 and 
Exendin-4. (A) Primary sequence 
alignment of the Glucagon-like 
peptide 1 (GLP-1) and Extendin-
4 (Ex-4) polypeptides is shown, 
where identical amino acid 
residues are underlined in red and 
chemically similar amino acids 




dimensional images of GLP-1 
structure (B)
19
 and Ex-4 structure 
(C)
20
 are shown. Structures were 
generated with Pymol software, 














 GLP-1R is a transmembrane protein expressed on the surface of pancreatic β-cells.18 
When bound to the GLP-1 ligand, GLP-1R induces the downstream production of cyclic 
adenosine monophosphate (cAMP), a secondary messenger in the incretin signaling pathway.
18
 
Analysis of the GLP-1R structure indicates its membership in the B family of G-protein coupled 
receptors (GPCRs).
21-22
 As is common among B family GPCRs, GLP-1R has a long, 
extracellular N- terminus including three disulfide bridges (Figure 3).
23-24
 Additionally, GLP-1R 
possesses a 7-pass transmembrane domain known as the integral membrane core domain (7TM), 
10 
 
and an intracellular C terminus (Figure 3).
22
 Class B GPCRs including GLP-1R are proposed to 
activate according to a two-step model (Figure 4).
18, 25-26
 First, the C-terminal region of GLP-1 is 




Figure 3. General Structure 
of GLP-1R. The snake 
diagram for rat glucagon-like 
peptide 1 receptor (GLP-1R) 
is shown; this structure shares 
95% homology with human 
GLP-1R. Transmembrane 
domains are denoted as TM1-
7; extracellular domains are 
represented as EC1-3, while 
intracellular domains are 
denoted as IC1-3. The 6 
highly-conserved N-terminal 
cysteine residues are 
highlighted in yellow. Blue 
circles indicate the residues 
necessary for agonist binding. 
Residues known to be 
involved in receptor activation 
are highlighted in green, while 
residues necessary for 
receptor internalization are 
shown in purple. Grey circles 
represent glycosylation sites. 






This localizes the N-terminus of GLP-1 to the  7TM domain in order to promote an interaction 
(Figure 4B).
26
 The second binding event causes a conformational change in the intracellular 
portion of the molecule, activating GLP-1R and triggering a signal cascade that ultimately 




Figure 4. Schematic of the GPCR 2-Step Binding and Activation Model. G-protein coupled 
receptor is represented in grey. (A)The C-terminal domain of the ligand, (blue), binds the N-
terminal extracellular domain (ECD) of the receptor. (B) This localizes the N-terminus of the 
ligand, (green), to the binding pocket of the receptor. (C) Upon binding to the N-terminus of the 
ligand, the receptor undergoes a conformational change and is activated, promoting intracellular 




 Evidence from previous studies has demonstrated that GLP-1R likely binds ligand 
according to this two-step model. For instance, Mann and colleagues isolated the extracellular N-
terminal domain of GLP-1R and found through subsequent binding studies that both extendin-4 
and GLP-1 bound to the truncated receptor with the same affinities observed in the wild type 
receptor.
27
 According to research by Gong and colleagues, ligand binding to the ECD is 
primarily controlled by the amphipathic α-helix domain of the ligand.14 For instance, the binding 
affinity between GLP-1R and Ex-4 was not affected if residues 1-8 of the N-terminus of Ex-4 
were deleted.
14, 28
 However, it is worth noting that truncated Ex-4 (9-39) behaved as an 
antagonist, whereas native Ex-4 is an agonist.
19, 28-29
  
 Additional study of the C-terminal region in both GLP-1 and Ex-4 demonstrated that the 
hydrophobic face of the α-helical domain was primarily involved in docking the ligand to the 
receptor without conferring receptor activation. For instance, Swedberg and colleagues revealed 
that chimeric proteins consisting of the N-terminal region of either Ex-4 or GLP-1 and an 
arbitrary α-helix at the C-terminal end could bind and activate GLP-1R without any significant 
12 
 
decrease in signal intensity.
30
 These results show that the initial ECD binding event on GLP-1R 
has little effect on subsequent receptor activation.  On the other hand, data from this study and 
others indicate that the ligand's N-terminus must be localized to the binding site in order for such 
activation to occur.
30-31
 The amphipathic nature of the α-helix allows  for both hydrophilic and 
hydrophobic interactions between ligand and receptor; however, a disproportionately high 
number of these interactions occur between hydrophobic residues.
19
 Crystal structures of the 

















of GLP-1R.  Lys
26
* is 
the only polar residue in the GLP-1 α-helix that is suspected to engage in polar interactions with 




  Consequently, it appears that nonpolar interactions in the 
ECD of GLP-1R localize the ligand to the receptor for subsequent interactions to promote 
binding.  
 
Figure 5. Docking Studies Show Representative Interactions Between N-Terminal Residues 
of GLP-1 and GLP-1R Binding Pocket. Non-covalent interactions between GLP-1 (yellow, 
etc.) and the GLP-1R binding cleft (cyan) are shown between transmembrane regions 1 and 2 
(A), as well as 5 and 6 (B). Residues of interest within the ligand are highlighted with various 
colors, while salient residues within the binding pocket itself are denoted as green (A) or red (B) 






 As discussed above, prior research suggested that removal of the first 8 N-terminal 
residues changed the pharmacological identity of Ex-4 from that of an agonist to an antagonist.
16, 
27
 Likewise, removal of the initial N-terminal residues of GLP-1 yielded a prohibitive impact on 
receptor activity.
11, 18, 20
 Thus, the N-terminal region of GLP-1 was implicated in activating GLP-
1R. Through a series of site-directed mutagenesis experiments, Dods and Donnelly predicted a 
model for ligand-mediated activation of GLP-1R (Figure 5).
20
 Within this model, the hydrophilic 
N-terminal residues are integrated into the 7TM region, disrupting the existing network of polar 
interactions at the base of the binding pocket.
20
 This, in turn, causes the conformational change 
associated with GLP-1R activation. Among these polar interactions, His
7









 is also projected to engage in 






 Kirkpatrick and colleagues 
generated similar predictions for polar interactions with His
7
*; however, they also indicated  






























 are also implicated in GP-1R activation.
19, 21, 
29





















T-0632: A small-molecule antagonist of GLP-1R 
 In a clinical setting, peptide-based GLP-1 analogs must be administered to diabetic 
patients several times a day because they are degraded or excreted in a matter of hours. These 
drugs are susceptible to hydrolysis in the digestive system and must be administered via 
injection. Such treatments are met with limited patient compliance due to discomfort and 
inconvenience. Therefore, engineering a small-molecule agonist to GLP-1R has distinct appeal, 
as it could be administered orally and has the potential for a longer half-life in vivo.
4-5, 32
 
Unfortunately, very few small-molecules are known to interact with GLP-1R.
32
 Among the 
existing classes of small-molecule GLP-1R substrates, (S)-3-[1-(2-fluorophenyl)-2,3-dihydro-3-
[(3-isoquinolinyl-carbonyl)amino]-6-methoxy-2-oxo-1H-indole] propanoate, (heretofore referred 
to as T-0632, or T-06), has received attention as a potential scaffold from which a GLP-1R 










Figure 6. T-0632 Molecular Structure. The 
molecular structure of T-0632 (T-06) is 








T-0632 is a man-made organic molecule that was initially synthesized to serve as an antagonist 
to the cholecystokinin receptor 1 (CCKA) in order to treat pancreatitis (Figure 6).
32
 However, 
Tibaduiza and colleagues found that T-06 not only inhibited CCKA receptor activity: it also 
reduced the activity of the incretin effect.
34
 Further investigations revealed this unwanted side 
effect to be the result of T-06 interaction with GLP-1R.
34
 Due to the diminished prevalence of 
cAMP, a downstream product of GLP-1R activation, in the presence of T-06, this molecule was 
classified as an antagonist.
32
 Although its effects on GLP-1R activity are significant, its binding 
affinity is relatively low; whereas T-06 binds the CCKA receptor on a sub-nanomolar scale, its 
affinity for GLP-1R is on a micromolar scale.
32
 As such, T-0632 is useful as an investigative tool 
for GLP-1R binding, but measures of its biological activity are more efficiently observed in 
systems expressing the CCKA receptor.
13
  
 Site-directed mutagenic studies of GLP-1R in the presence of T-06 revealed that the 




 Situated in the extracellular 
domain of GLP-1R, Trp
33
 and T-06 are suspected to interact via pi-stacking between the 
aromatic functional groups in each molecule (Figure 7).
34
 These interactions may stabilize the 
inactivated or "closed" state of GLP-1R, hence the reduction in activity.
32
 Bound to Trp
33
, T-06 
is separated from the 7TM domain by approximately 10 Angstroms.
32, 35
 Further investigation of 
16 
 
the interactions between T-06 and GLP-1R suggest that the carboxylic acid moiety of T-06 is 
localized to the 7TM binding cleft (Figure 7).
35
 For example, this acidic functional group is 
projected to engage in charge-charge interactions with Lys
288
 of the fourth transmembrane 
domain (TM4), among other residues.
35
 Such polar interactions in the binding cleft are 
reminiscent of those observed between GLP-1R and the N-terminal residues of GLP-1. Thus, the 
projected binding orientation of T-06 in GLP-1R provides a favorable platform for generating a 
small-molecule agonist to GLP-1R.  
 
Figure 7. Proposed Interactions Between T-06 and GLP-1R. Predicted noncovalent 
interactions between T-06 and GLP-1R are shown; this includes pi-stacking interactions between 
the isoquinoline group of T-06 and tryptophan 33 (W33), as well as the potential electrostatic 
interactions between the carboxylic acid moiety of T-06 and basic residues in the GLP-1R 





   
 
 Previously, T-0632 analogs have been generated in order to achieve alternate structural 
characteristics.
13, 35-36
 Among these analogs, Wilson generated a propyl amine form of T-0632 
(known as T-06 amine), in which the carboxylic acid moiety was substituted with that of a 
primary amine moiety.
13
 Not only does this T-06 analog possess possible alternative interactions 
with GLP-1R; its primary amine functional group has potential to serve as a C-terminal handle to 
17 
 
an amino acid sequence. The purpose of this study is to produce and investigate two T-06 
analogs, including a potential GLP-1 mimetic containing an N-terminal tripeptide (Figure 8). The 
biological activity of these compounds will be compared with that of the original T-0632 
molecule in vitro. Biological studies could improve insight into the spatial relationships between 
T-06 and the GLP-1 and CCKA receptors. Such studies would also illuminate the role of the His-
Gly-Glu tripeptide in GLP-1R binding and activation.  
 
Figure 8. Simplified Synthetic Mechanism. The molecular structures for the amine T-06 
precursor, T-06 nitrile (A), amine T-06 (B), and His-Gly-Glu-amine T-06 (C) are shown. 





 This study intends to generate an analog of T-0632 in which the carboxylic acid moiety is 
replaced with a primary amine (Figure 8B). In order to do this, amine T-06 will be generated 
through the reduction of its molecular precursor, T-0632 with a nitrile adduct. As of yet, the 
impact of the amine functional group on T-06 binding and activation of GLP-1R is unknown. 
Therefore, we will subject this compound to biological testing. The binding orientation of T-06 
amine is predicted to be different from that of T-06, as this basic functional group may disrupt 
the charge interactions between T-06 and the 7TM domain, particularly at Lys
288
. This disruption 
may impact the activity of GLP-1R, promoting a conformational change that stimulates 
18 
 
downstream cAMP production. Conversely, novel hydrostatic repulsions in this region could 
alter the orientation with which amine T-06 interacts with the receptor overall, reducing ligand-
receptor affinity.  
 In addition to amine T-06, an alternative T-06 analog and potential GLP-1 mimetic will 
be produced (Figure 8C). To accomplish this, a His-Gly-Glu tripeptide is coupled to the primary 
amine moiety of amine T-06 using solution-phase peptide synthesis. The His-Gly-Glu tripeptide 
was selected based on previous studies in which these GLP-1 residues were found to have the 
most significant impact on activation of the GLP-1 receptor (Table 1).
21
 Because solution-phase 
peptide synthesis can be carried out in mild conditions and is commonly associated with high 
yields, we hypothesize that peptide coupling to the amine T-06 analog will be a stable and 
efficient synthetic process.  
 In order to assay the biological activity of the amine T-06 and His-Gly-Glu-amine T-06 
analogs relative to the standard T-06 molecule, cell studies will be carried out in both GLP-1 and 
CCK1A receptors. In vitro assays will be conducted in HEK cell lines, stably expressing one of 
the above mentioned GPCRs. Biological activity will be quantified in terms of downstream 
cAMP production by these cellular receptors. These studies will be conducted at a collaborating 
laboratory in Mayo Clinic's Scottsdale, Arizona campus. If a change in the cAMP response is 
observed among the T-06 analogs, these results could bear pharmacological significance for 
T2DM treatment studies using small molecule drugs. For example, these experiments could 
provide insights into the structure-function relationship of GLP-1R, including the mechanisms of 
its binding and activation. Moreover, the relative biological activity of the proposed T-0632 




RESULTS AND DISCUSSION 
 
Reduction of T-0632 Nitrile  
  Amine T-0632 was produced from T-0632 nitrile through a nitrile reduction mechanism 
(Figure 9). The presence of unsaturated functional groups throughout the molecular structure of 
T-0632, including carbonyls, isoquinoline, and benzene rings, require sufficiently mild reducing 
conditions to prevent unwanted hydrogenation. Sodium borohydride is generally not a potent 
reducing agent against nitriles, amides, or other nitro compounds.
37
 However, in the presence of 
transition metal salts, sodium borohydride efficiently reduces nitrile to a primary amine through 
a mechanism that has not fully been elucidated.
38
 It is postulated that nitrile forms a complex 
with the metal boride surface, which in turn activates the nitrile and allows hydride addition to 
occur.
37
 The transition metals are hypothesized to behave as catalysts, generating boride salts and 
increasing the rate and yield of these hydrogenation reactions.  
 Synthesis of the propyl amine analog of T-0632 was approached using two separate 
techniques (Figure 10). In each case, the T-0632 nitrile analog was obtained from a member of 
the Haines laboratory. According to the first synthetic scheme designed by Wilson, (2014), 
sodium borohydride and cobaltous chloride were used to mediate reduction of the nitrile 
functional group.
13
 Previous syntheses of T-0632 amine using these methods were reported to 
produce the desired product at an experimental yield of 50%.
13
 However, repeated attempts of 
this protocol failed to convert the nitrile functional group to the amine. It has been noted 
throughout the relevant literature that nitrile reduction may have vastly different outcomes 
depending on small adjustments to the experimental conditions. For example, alternative 
transition metals have previously been used in nitrile reduction reactions: nickel(II) being among 
20 
 
the best and most characterized of these alternatives.
38-39
 Additionally, it is possible that nitrile 
reduction is facilitated by specific experimental conditions, such as an anhydrous environment or 
continuous exposure to hydrogen gas over the course of the reaction; this will be discussed in 





Figure 9. Synthetic schemes of T-0632 nitrile reduction methods. Reduction using cobalt 
chloride and sodium borohydride (A), and nickel (II) chloride and sodium borohydride with Boc 
anhydride added (B). 
 
 The second attempted technique, adapted from Caddick and colleagues, utilized sodium 
borohydride and nickel chloride to catalyze nitrile reduction.
39
 This protocol also incorporated 
21 
 
Boc anhydride to protect the newly formed primary amine from unwanted side reactions: namely 
dimerization through nucleophilic attack of one primary amine on the intermediate imine of 
another T-06 molecule, resulting in an aldimine (Figure 10B). The Boc-protected amine product 
was also more readily distinguishable from its reactants in NMR spectroscopic analysis. Sodium 
borohydride was added to a stirring solution of T-06 nitrile, nickel chloride, and Boc anhydride 
over a period of 30 minutes (Figure 9). The reaction was initially conducted at 0°C in order to 
minimize thermally-driven byproduct formation. After an additional 16 hours of stirring at room 
temperature, the reaction was halted with ethylenediamine and subsequently diluted in ethyl 
acetate. The organic layer was washed with saturated sodium bicarbonate and dried with 
anhydrous sodium sulfate before solvent and reactants with low boiling points were removed 
under reduced pressure. NMR analysis suggested that nitrile reduction was unsuccessful 
(Appendix 1).  Proposed improvements to the existing nitrile reduction protocol primarily 
involved isolated changes to the previously utilized reagents. For example, Khurana and 
colleagues reported that the experimental yields of primary amines through nitrile reduction with 
nickel chloride could be improved by performing the reaction under anhydrous conditions in 
ethanol.
41
 Moreover, the efficiency of nickel-catalyzed nitrile reduction reactions was improved 
by applying slightly pressurized hydrogen gas to the  system, indicating that it was a 




 A second iteration of this protocol was conducted, in which initial reactants were added 
under a steady stream of nitrogen gas and the overnight reaction was carried out in low-pressure 
catalytic hydrogenation conditions with ethanol as the solvent.
49
 The products were purified and 
a 30% yield of Boc-protected T-06 amine was confirmed with 1-dimensional and 2-dimensional 
22 
 
NMR spectroscopy (Appendix 2; Appendix 3). Because the O-tert-butyl functional group is 
sensitive to protonation and subsequent dissociation, Boc deprotection was accomplished with 
trifluoroacetic acid (TFA) and anisole. As a result, a tert-butyl cation dissociates from the Boc 
system to be subsequently trapped by anisole via electrophilic aromatic substitution. Electronic 
rearrangement of the remaining carbamic acid releases carbon dioxide from the solution, 
producing the primary T-06 amine (Mechanism not shown). Trituration of the product in a 
solution of dichloromethane and hexanes at a 1:9 ratio yielded pure amine T-06 salt (Appendix 









































of nitrile to imine to 
primary amine (A), 
dimerization through 
aldimine formation 
(B), and the synthesis 




Synthesis of His-Gly-Glu Tripeptide   
 Tripeptide synthesis was initially attempted independent of the propyl amine T-0632 
analog according to the experimental mechanism proposed by Smith (2008).
42
 These reactions 
were carried out according to a solution-phase peptide synthesis mechanism. Residues were 
added in a carboxy-to-amino terminal direction, in which each of the subsequent amino acids 
was protected at its amino terminus with an Fmoc functional group. Therefore, peptide bond 
formation was limited to the N-terminus of the preceding amino acid and the C-terminus of the 
subsequent residue.  
 Fmoc-protected glycine was added to Glu(OtBu)-OMe, in an 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) coupling reaction in which triethylamine, 
hydroxybenzotriazole (HOBt), and EDC in dichloromethane were added to the amino acid 
reactants and stirred for three hours at room temperature. Nucleophilic attack of glycine's 
hydroxyl group on the partially positive carbon of EDC produces a relatively stable leaving 
group at the C-terminus of glycine. Thus activated, the C-terminal carbonyl of glycine is 
susceptible to nucleophilic attack by the HOBt hydroxyl group. The resulting activated ester 
serves as a stable leaving group for subsequent amide bond formation. The primary amine of 
Glu(OtBu)-OMe is attracted to the partially positive carbonyl of glycine's C-terminus. Glutamic 
acid subsequently attacks glycine, displacing the HOBt ester and producing the Fmoc-Gly-
Glu(OtBu)-OMe dipeptide (Figure 11). This product was isolated from the organic layer after 
being washed three times with water and dried over sodium sulfate. The product was further 
isolated following vacuum filtration and purification via flash chromatography. Proton NMR 




Figure 11. Synthesis of Fmoc-Gly-Glu(OtBu)-OMe via EDC coupling. 
 
 Fmoc deprotection of the amino terminus of glycine was attempted by dissolving the 
dipeptide product in 20% piperidine in DMF and stirring for 15 minutes. The reaction was 
diluted in dichloromethane and neutralized by three washes with 0.1 M HCl. This low-pH 
environment was predicted to protonate the deprotected dipeptide, generating a charged, water-
soluble form of the compound. Therefore, the aqueous layer was collected and lyophilized in 
order to remove excess water. However, NMR analysis revealed that the O-methyl functional 
group of the protected C-terminus of glutamic acid was present at a lower concentration than 
other functional groups in the spectrum (Appendix 6). This data suggests that the deprotected 
amino terminus of glycine underwent nucleophilic attack on the C-terminal carbonyl of glutamic 
acid, generating a 6-membered ring (Figure 12). Smith reported similar instances of cyclization 
reactions, in which the dipeptide produced a 6-membered ring due to intramolecular nucleophilic 
26 
 
attack of the de-protected N-terminus of glycine on the C-terminus of glutamic acid, causing the 
covalently-bound methyl ester to dissociate.    
 
Figure 12. Proposed mechanism of Gly-Glu(OtBu)-OMe cyclization following Fmoc 
deprotection. 
A second attempt at tripeptide synthesis was made in which the primary amine of the 
previously-synthesized T-06 amine was used as a handle for solution-phase peptide synthesis. 
EDC coupling techniques were used to covalently bind the C-terminus of  Fmoc-Glu(OtBu)-OH-
to the propyl amine functional group of T-06 amine. As previously described, the two species 
were combined in the presence of triethylamine, HOBt and EDC (Figure 13). Reactants were 
stirred for 18 hours and extracted three times with water. After treatment with anhydrous sodium 
sulfate, the organic layer was evaporated under reduced pressure and examined with NMR 
spectroscopy. Following purification, it was confirmed that Fmoc-Glu(OtBu)- amine T-06 was 
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produced at a 52% yield (Appendix 7). 
Figure 13. Addition (A) and deprotection (B) of Fmoc-Glu(OtBu)-OH to amine T-0632. 
 
Based on the mechanism of Fmoc-Glu(OtBu)-OH addition, as well as spectral indicia 
from NMR analysis, chirality was expected at glutamic acid’s α-carbon. However, flash 
chromatography and other available separation techniques lacked sufficient selectivity to isolate 
these diastereomers; the respective polarities of these isomers may be nearly equivalent. High-
performance liquid chromatography (HPLC) may provide the resolution necessary to separate 
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these species.  Of the unreacted T-06 amine, two additional attempts were made to add Fmoc-
Glu(OtBu)-OH, neither of which was successful. This failure to react was attributed to the 
chemical identity of the T-06 analog; during the nitrile reduction reaction, for instance, it is 
possible that the intermediate imine functional group was hydrolyzed, producing T-06 alcohol 
rather than  T-06 amine (Fig. 10C). These products were not differentiable though spectroscopic 
analysis due to the relative impurity of the compound, yet would have vast differences in 
reactivity during peptide bind formation. Additional NMR analysis of the unreactive samples 
shows a difference in the chemical environment of the T-06 alkyl chain; the downfield shift of 
these peaks supported the presence of a hydroxyl group at the primary amine locus of amine T-
0632 (Appendix 8). 
 Fmoc-deprotection of the glutamic acid was accomplished by a 15-minute reaction with 
20% piperidine in DMF. The reaction was halted by dissolution in water, followed by the 
removal of solvent and reactants via lyophilization. Due to mechanical failure of the NMR 
machine, no data is available for the glutamic acid deprotection event. Glutamic acid 
deprotection was immediately followed by a coupling reaction with Fmoc-Gly-OH, in which the 
EDC coupling protocol described above was used to link Fmoc-Gly-OH to the N-terminus of the 
glutamic acid handle. Flash chromatography over a solvent gradient of ethyl acetate in hexanes 




Figure 14. Addition (A) and deprotection (B) of Fmoc-Gly-OH to Glu(OtBu)-amine T-06.  
 
 In order to complete the synthesis of His-Gly-Glu-amine T-0632, another Fmoc-
deprotection reaction was carried out by dissolving Fmoc-Gly-Glu(OtBu)-T-06 amine in 20% 
30 
 
piperidine in DMF (Figure 14B). Following dilution with water, the organic layer was extracted 
with dichloromethane and analyzed with NMR spectroscopy. These results supported glycine 
deprotection (Appendix 10). Boc-His(Boc)-OH was added into a solution of Gly-Glu(OtBu)-T-
06, EDC, HOBt, triethylamine, and dichloromethane (Figure 15). After approximately 3 hours of 
stirring, the organic layer was washed three times with water and subjected to NMR analysis. 
Due to its miniscule sample size, this product could not be purified further. However, the 
spectroscopic data supports the successful addition of Boc-His(Boc)-OH to the existing 
dipeptide-amine T-06 analog. Additional purification and spectroscopic investigation will 
confirm the identity of this final synthetic product (Appendix 11).   
 









 Synthesis of the amine T-0632 analog was achieved through nitrile reduction with 
sodium borohydride and nickel chloride in mild catalytic hydrogenation conditions. This method 
had more reproducible synthetic success and roughly equivalent experimental yields when 
compared to previous T-06 nitrile reduction protocols utilizing sodium borohydride and 
cobaltous chloride.  
 T-06 amine served as a suitable synthetic handle for solution phase peptide synthesis. The 
systematic addition of amino acids necessary to produce the desired His-Gly-Glu tripeptide was 
achieved without the cyclization or side reactions observed in independent tripeptide synthesis 
reactions. This synthetic protocol may be applicable to the production of alternative small 
molecule-peptide hybrid compounds.  
 Biological testing of T-06 amine and tripeptide-amine T-06 analogs will be conducted at 
Mayo Clinic in order to assess their respective capacities to bind and activate the GLP-1 
receptor. T-06 amine is predicted to cause conformational shifts within the binding pocket due to 
electrostatic repulsions among the positive transmembrane residues of GLP-1R. The tripeptide-
T-06 amine analog is further hypothesized to mimic ligand-receptor dynamics at the GLP-1R 
active site. Significant differences in the binding affinity or receptor activation protocols of either 
of these compounds as compared to T-0632 would support their future investigation and 








All reagents were purchased from Sigma-Aldrich (St. Louis, MO). Solvent evaporation 
under reduced pressure was accomplished with a Buchi Rotavapor R-114 with Buchi Waterbath 
B-480 (Buchi, New Castle, DE). Lyophilization was carried out at 100 mTorr and -85°C on a 
VirTis BenchTop Pro Freeze Dryer (SP Scientific, Gardiner, NY). 
1
H and 2-dimensional Nuclear 
Magnetic Resonance Spectroscopy experiments were conducted with a Bruker 500 MHZ NMR 
Spectrometer (Bruker Instruments, Billerica, MA). All NMR samples were dissolved in 
deuterated chloroform, with tetramethylsilane (TMS) as the standards.  
Thin-layer chromatography was conducted with Merck 60-F254 pre-coated silica gel 
plates and 250 nm UV light. Flash chromatography was carried out using a Biotage Flash 
Purification system with detection wavelengths set to 254 nm and 220 nm. Fractions absorbing  
at 254 nm were collected for subsequent analysis. Samples were loaded onto a Biotage SNAP 
Ultra 1 g silica samplet and run through a 10g pre-packed silica cartridge.  
 
Reduction of T-0632 Nitrile with Cobaltous Chloride and Sodium Borohydride 
 In an oven-dried flask, pure T-0632 nitrile (0.030 g, 0.0586 mmol) and cobaltous chloride 
(0.0279 g, 0.117 mmol) were dissolved in 0.352 mL of methanol, producing a bright blue 
solution. Tetrahydrofuran (0.75 mL) was added to the reaction and heat was applied to the 
system. Upon returning to room temperature, 0.222 g (0.586 mmol) sodium borohydride was 
added over a 5-minute period, during which the solution turned black and emitted heat and 
hydrogen gas. The system was sealed with a septum cap and stirred at 20°C for one hour. 
Hydrochloric acid was added to the system until the solution turned pink. Subsequently, 8 mL 
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concentrated sodium hydroxide was added to the system in order to produce a pH 9 solution; the 
color transitioned from pink to grey-blue. Dichloromethane was used to extract the organic layer, 
which was then washed with saturated sodium chloride. The organic layer was subsequently 
dried with sodium sulfate and filtered. The rose-colored product was then subjected to solvent 
evaporation under reduced pressure. The resulting NMR indicated that the solid material 
obtained was predominantly composed of starting material. The aqueous layer from the organic 
extraction was washed in concentrated sodium hydroxide in order to deprotonate the T-06 amine 
salt and subjected to a second extraction with dichloromethane. After drying, filtration, and 
evaporation, the new organic layer was analyzed with NMR spectroscopy; there was no evidence 
of product in this spectrum. 
1
HNMR of T-0632 nitrile in CDCl3 (Appendix 1): δ2.3 (m, 1H, H of 
alkyl chain), δ2.5 (t, 2H, H of alkyl chain), δ2.7 (m, 1H, H of alkyl chain), δ3.7 (s, 3H, -OCH3), 
δ6.3 (s, 1H, H of m-anisidine), δ6.6 (d, 1H, m-anisidine), δ7.3‐8.1 (m, 1H, H of m-anisidine; 4H, 
H of of difluorobenzene; 4H, H of benzene of isoquinoline), δ8.5 (s, 1H, amine) δ8.9 (s, 1H, H of 
N-containing ring of isoquinoline), δ9.1 (s, 1H, H of N-containing ring of isoquinoline). 
 
Reduction of T-0632 Nitrile with Nickel Chloride and Sodium Borohydride 
   T-0632 nitrile (0.3 g, 0.619 mmol) dissolved in 5 mL methanol was placed in an oven-
dried flask under a stream of nitrogen gas. The system was brought to 0°C over ice. To this 
solution, Boc-anhydride (270.26 mg, 1.24 mmol) and nickel chloride (8.02 mg, 0.0619 mmol) 
were added, producing a light violet solution. Over a 30-minute period, sodium borohydride 
(164.08 mg, 4.34 mmol) was stirred into solution. Nitrogen gas was applied to the system at all 
times between the addition of reagents. The solution was diluted in 10 mL ethanol and subjected 
to 20 psi under hydrogen gas. This reaction was shaken for 16 hours, during which time a white 
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precipitate was formed. The precipitate was treated with ethylenediamine (41.4μL, 0.62 mmol) 
and stirred for 30 minutes before solvent evaporation. Ethyl acetate (15.5 mL) was used to 
dissolve the evaporated product and the organic layer was subsequently extracted with 3 rinses of 
saturated sodium bicarbonate. The organic layer was dried with sodium sulfate, filtered, and 
evaporated under reduced pressure. Purification of the resulting white precipitate was 
accomplished through flash chromatography: crude product was dissolved in hexanes and loaded 
into the silica gel samplet. The column was run over a concentration gradient of 35-38% ethyl 
acetate in hexanes. Unreacted T-06 nitrile began to elute at a concentration of 35% ethyl acetate, 
while the desired product eluted at an approximate concentration of 37% ethyl acetate. Pure Boc-
protected amine T-0632 was confirmed via 
1
H NMR. 1HNMR of Boc-protected amine T-0632 in 
CDCl3 (Appendix 2): δ1.47 (s, 9H, Boc), δ1.3-1.8 (m, 3H, H of alkyl chain), δ2.2 (s, 2H, H of 
alkyl chain), δ2.7 (s, 1H, alkyl chain), δ3.17 (m, 2H, alkyl chain)  δ3.7 (s, 3H, -OCH3), δ4.5 (s, 
3H, primary amine), δ6.2 (s, H of m-anisidine, 1H), δ6.6 (d, 1H, H of m-anisidine), δ7.2-8.0 (m; 
1H, H of m-anisidine; 4H, H of fluorobenzene; 4H, H of benzene of isoquinoline, 4H), δ8.5 (d, 
1H, amine), δ8.9-9.0 (s, 1H, H of N-containing ring of isoquinoline), δ9.1 (s, 1H, H of N-
containing ring of isoquinoline). Additionally, COSY NMR spectroscopy was used to identify 
protons in the alkyl chain to confirm successful nitrile reduction. The most notable interaction 
was that observed at the crosspeak between 3.17 ppm, representing two hydrogens in the alkyl 
chain, and the broad peak at 4.5 ppm, which was associated with the primary amine functional 
group (Appendix 3). 
Synthesis of Amine T-0632 via Boc Deprotection 
 Cold trifluoroacetic acid (5mL) and anisole (126μL) were added to pure Boc-protected 
amine T-0632 (0.11g, 0.193 mmol). The reaction stirred for 1 hour at room temperature. 
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Subsequently, the brown gel was dissolved in a 1:1 mixture of dichloromethane and hexanes and 
evaporated under reduced pressure three times. The reaction was then treated with a 1:1 solution 
of dichloromethane and hexanes and stored for 16 hours at -18°C. Trituration of the product with 
a 1:9 ratio of dichloromethane and hexanes yielded an off-white, crystalline precipitate. 
1
HNMR 
analysis confirmed the successful generation of the amine T-06 salt.  
1
H-NMR of amine T-0632 
in CDCl3 (Appendix 4): δ1.3-1.8 (m, 3H, H of alkyl chain), δ2.2 (s, 2H, H of alkyl chain), δ2.7 
(s, 1H, alkyl chain), δ3.17 (m, 2H, alkyl chain)  δ3.7 (s, 3H, -OCH3), δ5.4 (s, 3H, primary 
amine), δ6.2 (s, H of m-anisidine, 1H), δ6.6 (d, 1H, H of m-anisidine), δ7.2-8.0 (m; 1H, H of m-
anisidine; 4H, H of fluorobenzene; 4H, H of benzene of isoquinoline, 4H), δ8.5 (d, 1H, amine), 
δ8.9-9.0 (s, 1H, H of N-containing ring of isoquinoline), δ9.1 (s, 1H, H of N-containing ring of 
isoquinoline). 
Production of the His-Gly-Glu tripeptide 
Synthesis of Fmoc-Gly-Glu(OtBu)-OMe dipeptide 
 Glu(OtBu)-OMe (0.894 g) and Fmoc-Gly-OH (1.24 g) were mixed together in a solution 
consisting of triethylamine (0.578 mL), HOBt (0.564 g), EDC (0.80 g), and 178.8 mL of 
dichloromethane. After three hours of stirring, the solution was rinsed three times with water in 
order to remove aqueous reagents. The organic layer was then dried with sodium sulfate, filtered, 
and its solvent evaporated under reduced pressure. The resulting honey-colored gel was analyzed 
via NMR spectroscopy. 
1
HNMR analysis suggested that the desired product was generated. 
1
H 
NMR of Fmoc-Gly-Glu(OtBu)-OMe (Appendix 5):
 δ 1.42 (s, 9H, t-butyl H), δ 1.89-2.00 (m, 1H, 
βCGluHA), δ 2.09-2.25 (m, 1H, βCGluHB), δ 2.3-2.45 (t, 2H, γCGlu), δ 3.76 (s, 3H, -OMe), δ 3.85 
(t, 2H, αCGly H), δ 4.51-4.55 (q, 1H, αCGlu H), δ 6.2-6.3 (s, 1H, Gly amide H), δ 6.84 (d, 1H, Glu 




Deprotection of Fmoc-Gly-Glu(OtBu)-OMe dipeptide 
 The existing Fmoc-Gly-Glu(OtBu)-OMe dipeptide was dissolved in 20% piperidine in 
DMF and stirred for 15 minutes at room temperature. Quenching with three rinses of 0.1 M 
hydrochloric acid halted the reaction. Aqueous solvent and the polar reactants trapped therein 
were removed via lyophilization. In this experiment, several rounds of overnight lyophilization 
were necessary to sufficiently isolate the product from piperidine. Subsequent analysis of the 
deprotected product via NMR spectroscopy revealed that cyclization had occurred, as evinced by 
the loss of the O-methyl protecting group at the C-terminus of Glu(OtBu)-OMe. . 
1
H NMR of 
cyclized Gly-Glu(OtBu)-OMe (Appendix 6):
 δ 1.42 (s, 9H, t-butyl H), δ 1.89-2.00 (m, 1H, 
βCGluHA), δ 2.09-2.25 (m, 1H, βCGluHB), δ 2.3-2.45 (t, 2H, γCGlu), δ 3.85 (t, 2H, αCGly H), δ 4.51-
4.55 (q, 1H, αCGlu H), δ 6.2-6.3 (s, 1H, Gly amide H), δ 6.6 (d, 1H, Glu amide), δ 7.44-7.62 (m, 
9H, Fmoc-- residual dissociated product from deprotection, as indicated by slight changes in the 
number and integration values of Fmoc-associated peaks). 
 
Attachment of Fmoc-Glu(OtBu)-OH to Amine T-0632 
 In a dry flask, amine T-0632 salt (0.076 g, 0.162 mmol) , Fmoc-Glu(OtBu)-OMe (0.069 
g, 0.162 mmol), HOBt (0.025 g, 0.162 mmol), EDC (0.31 g, 0.162 mmol), and triethylamine 
(49.1 μL, 0.32 mmol) were combined and cooled to 0°C. After 30 minutes of stirring, the 
reaction was allowed to warm to room temperature and stir for an additional 18 hours. The 
organic layer was extracted with three rinses of water (approximately 5 mL each). After being 
dried with sodium sulfate, filtered, and evaporated under reduced pressure, the sample was 
lyophilized for 24 hours in order to remove excess triethylamine. The sample was subsequently 
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separated over a concentration gradient of 20-45% ethyl acetate in hexanes via flash 
chromatography. Unreacted T-06 amine began to elute at a concentration of 37% ethyl acetate. 
In order to elute the desired product, a second concentration gradient between 45-100% ethyl 
acetate in hexanes was run for this sample; Fmoc-Glu-amine T-0632 was detected at a 





H-NMR of Fmoc-Glu(OtBu)-amine T-0632 in CDCl3 (Appendix 7): δ1.3-1.8 (m, 
3H, H of alkyl chain), δ 1.42 (s, 9H, t-butyl H), δ 1.89-2.00 (m, 1H, βCGluHA), δ 2.09-2.25 (m, 
1H, βCGluHB), δ2.2 (s, 2H, H of alkyl chain), δ 2.3-2.45 (t, 2H, γCGlu), δ2.7 (s, 1H, alkyl chain), 
δ3.17 (s, 1H, alkyl chain),  δ3.7 (s, 3H, -OCH3), δ 4.51-4.55 (q, 1H, αCGlu H), δ6.2 (s, H of m-
anisidine, 1H), δ 6.6 (d, 1H, Glu amide), δ 7.44-7.62 (m, 9H, Fmoc), δ6.6 (d, 1H, H of m-
anisidine), δ7.2-8.0 (m; 1H, H of m-anisidine; 4H, H of fluorobenzene; 4H, H of benzene of 
isoquinoline, 4H), δ8.5 (d, 1H, amine), δ8.9-9.0 (s, 1H, H of N-containing ring of isoquinoline), 
δ9.1 (s, 1H, H of N-containing ring of isoquinoline). 
 Experimental yield for this protocol was approximately 50%. Subsequent attempts to 
attach Fmoc-Glu(OtBu)-OH to the remaining unreacted T-06 amine using the coupling 
procedure detailed above were unsuccessful. NMR analysis of the apparently unreactive T-06 
amine produced the following results (Appendix 8): δ1.3-1.8 (m, 3H, H of alkyl chain), δ2.2 (s, 
2H, H of alkyl chain), δ2.7 (s, 1H, alkyl chain), δ3.48 (s, 2H, alkyl chain)  δ3.7 (s, 3H, -OCH3), 
δ5.4 (s, 3H, primary amine), δ6.2 (s, H of m-anisidine, 1H), δ6.6 (d, 1H, H of m-anisidine), δ7.2-
8.0 (m; 1H, H of m-anisidine; 4H, H of fluorobenzene; 4H, H of benzene of isoquinoline, 4H), 
δ8.5 (d, 1H, amine), δ8.9-9.0 (s, 1H, H of N-containing ring of isoquinoline), δ9.1 (s, 1H, H of 




Deprotection of Fmoc-Glu(OtBu)-Amine T-0632 and Addition of Fmoc-Gly-OH  
 Fmoc-Glu-amine T-0632 (0.025 g, 0.028 mmol) was stirred with 20% piperidine (1 mL) 
for 15 minutes at room temperature. The reaction was then diluted in 20 mL of water and the 
system was lyophilized for 24 hours in order to remove aqueous solvent and reagents with 
sufficiently low boiling points. Subsequently, the resulting off-white precipitate was dissolved in 
0.5 mL dimethylformamide and combined with Fmoc-Gly-OH (0.025 g, 0.084 mmol), HOBt 
(0.025 g, 0.084 mmol), EDC (0.016 g, 0.084 mmol), and triethylamine (25.0 μL, 0.168 mmol). 
The reaction was stirred at 0°C for 30 minutes, followed by 18 hours of stirring at room 
temperature. The organic layer was extracted with three rinses of water (approximately 5 mL 
each). After being dried with sodium sulfate, filtered, and evaporated under reduced pressure, the 
solvent was evaporated under reduced pressure. The sample was subsequently separated over a 
concentration gradient of 60-80% ethyl acetate in hexanes via flash chromatography. Elution of 
neither product nor reactant was observed. A second concentration gradient was run for this 
sample between 0-5% ethanol in ethyl acetate; the chromatogram for this experiment did not 
demonstrate absorbance at 254 nm at any point. Fractions were systematically collected, their 
solvents evaporated under reduced pressure, and their contents characterized via NMR 
spectroscopy. This procedure revealed characteristic T-06 amine peaks in a small subset of the 
total fractions collected. Due to the low concentration of eluent, a 12,000-scan NMR was 
conducted in order to elucidate its identity at higher resolution. The structure of Fmoc-Gly-
Glu(OtBu)-amine T-06 was confirmed via 
1
H NMR at 12,000 scans. 
1
H-NMR of Fmoc-Gly-
Glu(OtBu)-amine T-0632 in CDCl3 (Appendix 9): δ1.3-1.8 (m, 3H, H of alkyl chain), δ 1.42 (s, 
9H, t-butyl H), δ 1.89-2.00 (m, 1H, βCGluHA), δ 2.09-2.25 (m, 1H, βCGluHB), δ2.2 (s, 2H, H of 
alkyl chain), δ 2.3-2.45 (t, 2H, γCGlu), δ2.7 (s, 1H, alkyl chain), δ3.7 (s, 3H, -OCH3), δ 3.85 (t, 
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2H, αCGly H), δ 4.51-4.55 (q, 1H, αCGlu H), δ 6.2-6.3 (s, 1H, Gly amide H), δ6.2 (s, H of m-
anisidine, 1H),δ 6.6 (d, 1H, Glu amide), δ6.6 (d, 1H, H of m-anisidine), δ7.2-8.0 (m; 1H, H of m-
anisidine; 4H, H of fluorobenzene; 4H, H of benzene of isoquinoline, 4H), δ8.5 (d, 1H, amine), 
δ8.9-9.0 (s, 1H, H of N-containing ring of isoquinoline). 
 
Deprotection of Fmoc-Gly-Glu(OtBu)-Amine T-0632 
 In order to remove the Fmoc functional group from the amino terminus of glycine, Fmoc-
Gly-Glu(OtBu)-amine T-06 (0.0012 g, 0.0013 mmol) was dissolved in 500 μL 20% piperidine in 
DMF and permitted to stir at room temperature for 15 minutes. The reaction was halted by 
dilution in 3 mL water. Two 24-hour lyophilization periods were necessary to remove excess 
piperidine from solution in order to prevent unwanted nucleophilic attacks on the amine T-06 
analog. Low product concentration warranted NMR analysis at 24,000 scans to achieve sufficient 
resolution to determine the identity of deprotected Gly-Glu(OtBu)-amine T-06. 
1
H-NMR of Gly-
Glu(OtBu)-amine T-0632 in CDCl3 (Appendix 10): δ1.3-1.8 (m, 3H, H of alkyl chain), δ 1.42 (s, 
9H, t-butyl H), δ 1.89-2.00 (m, 1H, βCGluHA), δ 2.09-2.25 (m, 1H, βCGluHB), δ2.2 (s, 2H, H of 
alkyl chain), δ 2.3-2.45 (t, 2H, γCGlu), δ2.7 (s, 1H, alkyl chain), δ 3.3 (t, 2H, αCGly H), δ3.7 (s, 
3H, -OCH3), δ 4.51-4.55 (q, 1H, αCGlu H), δ 6.2-6.3 (s, 1H, Gly amide H), δ6.2 (s, H of m-
anisidine, 1H), δ6.6 (d, 1H, H of m-anisidine), δ 6.6 (d, 1H, Glu amide), δ7.2-8.0 (m; 1H, H of 
m-anisidine; 4H, H of fluorobenzene; 4H, H of benzene of isoquinoline, 4H), δ8.5 (d, 1H, 






Addition of Boc-His(Boc)-OH to Gly-Glu(OtBu)-amine T-06 
 In order to complete the tripeptide of the His-Gly-Glu(OtBu)-amine T-06 analog, Gly-
Glu(OtBu)-amine T-06 (0.0022 g, 0.0031 mmol), Boc-His(Boc)-OH (0.00165 g, 0.00372 mmol), 
HOBt (0.0125 g, 0.0925 mmol), EDC (0.0006 g, 0.00312 mmol), and triethylamine (10 μL, 
0.00725 mmol) were dissolved in 0.5 mL dichloromethane. Initial reaction occurred at 0°C; 
however, 30 minutes into the reaction, the solution warmed to room temperature and was stirred 
for an additional 18 hours. Organic extraction with a solution of water and dichloromethane 
produced a yellow organic layer and a colorless aqueous layer. The organic layer was 
subsequently dried with anhydrous sodium sulfate, filtered, and evaporated under reduced 
pressure, producing a dark red glass. 
1
HNMR analysis was conducted for 10,000 scans in order 
to elucidate the chemical structure of the resulting compound at sufficient resolution to 
compensate for its low concentration. Spectroscopic evidence supports the production of Boc-
His(Boc)-Gly-Glu(OtBu)-amine T-06; however, the strength of this conclusion is mitigated by 
the low concentration of product relative to the concentration of solvent and other reagents. 
Unfortunately, the total quantity of product was too small to undergo further purification. 
1
H-
NMR of Boc-His(Boc)-Gly-Glu(OtBu)-amine T-0632 in CDCl3 (Appendix 11): δ1.3-1.8 (m, 
3H, H of alkyl chain), δ 1.42 (s, 9H, t-butyl H), δ 1.89-2.00 (m, 1H, βCGluHA), δ 2.09-2.25 (m, 
1H, βCGluHB), δ2.2 (s, 2H, H of alkyl chain), δ 2.3-2.45 (t, 2H, γCGlu), δ2.7 (s, 1H, alkyl chain), δ 
3.03-3.22 (m, 2H, βCHis H), δ 3.4 (t, 2H, αCGly H), δ3.7 (s, 3H, -OCH3), δ 4.51-4.55 (q, 1H, 
αCGlu H), δ 5.6-5.7 (s, 1H, αCHis H), δ 6.2-6.3 (s, 1H, Gly amide H), δ6.2 (s, H of m-anisidine, 
1H), δ6.6 (d, 1H, H of m-anisidine), δ 6.6 (d, 1H, Glu amide), δ7.2-8.0 (m; 1H, H of m-anisidine; 
4H, H of fluorobenzene; 4H, H of benzene of isoquinoline, 4H), δ8.5 (d, 1H, amine), δ8.9-9.0 (s, 
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H NMR of Boc-protected T-06 amine 
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H NMR of Boc-His(Boc)-Gly-Glu(OtBu)-amine T-0632 
